Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4
Status:
Completed
Trial end date:
2017-09-08
Target enrollment:
Participant gender:
Summary
The objective of the investigators was to delineate the efficacy and safety of Ombitasvir,
paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian
naïve patients